Competitive Intelligence In Breast Cancer: Tracking The Evolving HR+ HER2-Ve Breast Cancer Landscape
A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor ...
DelveInsight Business Research, LLP: Competitive Intelligence in Breast Cancer: Tracking the Evolving HR+ HER2-ve Breast Cancer Landscape
A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor the evolving breast cancer competitive intelligence ...
EuropaWire4d
Roche Expands FDA Approval of PATHWAY® HER2 Test for HER2-Ultralow Breast Cancer Status
Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HE ...
manilatimes5d
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, ...